Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

This phase I trial was designed to determine the safety and maximum tolerated dose (MTD) of tipifarnib in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Furthermore, the pharmacokinetics of each of these agents was evaluated. Patients were treated with tipifarnib...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegel-Lakhai, W S, Crul, M, Zhang, S, Sparidans, R W, Pluim, D, Howes, A, Solanki, B, Beijnen, J H, Schellens, J H M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361514/
https://www.ncbi.nlm.nih.gov/pubmed/16251868
http://dx.doi.org/10.1038/sj.bjc.6602850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361514/
https://www.ncbi.nlm.nih.gov/pubmed/16251868
http://dx.doi.org/10.1038/sj.bjc.6602850

Ejemplares similares